IGF1 Controls Appetite-Regulating Neuropeptides in the Brain, But High Insulin Levels Block This Signaling

Researchers used RT-qPCR and single-cell RNA sequencing to characterize IGF1 receptor expression in hypothalamic neuron populations. Mouse and human cell models were treated with IGF1 to assess neuropeptide expression changes. The effects of fasting, nutrient availability, and circadian rhythms on IGF1 binding proteins were measured. Hyperinsulinemia conditions were modeled to study IGF1 resistance mechanisms via the PI3K-FOXO1 pathway.

Understanding how growth factor signaling regulates appetite-controlling neuropeptides is fundamental to treating obesity and metabolic disease. The discovery that high insulin levels cause IGF1 resistance in the hypothalamus creates a new framework for understanding why metabolic dysfunction leads to appetite dysregulation — and potentially identifies new therapeutic targets.

This study connects the dots between metabolic hormones (insulin, IGF1) and brain neuropeptide circuits that control eating behavior. The finding that hyperinsulinemia causes IGF1 resistance in appetite-controlling neurons provides a molecular explanation for why metabolic dysfunction creates a vicious cycle: high insulin → impaired appetite regulation → more eating → more insulin resistance.

This is primarily an in vitro/cell model study. While both mouse and human models were used, the findings need validation in intact animal models and human subjects. The complexity of hypothalamic neuropeptide circuits means that isolated cell responses may not fully predict in vivo outcomes. The hyperinsulinemia-IGF1 resistance mechanism is novel and requires independent confirmation.